Malignant mesothelioma

Our plain-English summary of Malignant mesothelioma, by E. Heyderman, P.D. Ridley (Journal of the Royal Society of Medicine, 1989).

The study

• Authors: E. Heyderman, P.D. Ridley
• Journal: Journal of the Royal Society of Medicine
• Published: 1989;82(9):571-3
• Type of article: Comment, Letter
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

In plain English

This is a letter to the editor, not a full research paper. The authors were responding to an earlier article by Rudd. That article described laboratory staining techniques used to tell malignant mesothelioma apart from adenocarcinoma that has spread (metastasized) from elsewhere. The authors cautioned that these stains may be of value but that great care must be taken in choosing the antibodies used. They briefly described their own earlier study, which compared three markers (CEA, EMA and cytokeratin) in tissue from 26 pleural mesotheliomas and 39 lung carcinomas. They confirmed that CEA was absent in the mesotheliomas, but 10 of the 39 lung carcinomas were also CEA-negative. They felt the other markers added little to examining the tissue's appearance under the microscope. In some mesotheliomas, a cytokeratin stain called CAM 5.2 showed a 'falling-apart' pattern that the authors had not seen in adenocarcinomas. However, when that pattern was absent, the result was inconclusive. The authors also noted that cytokeratin, which they had once read as a sign of mesothelial origin in spindle cells, has since been found in mesenchymal tissues and tumours. The letter does not discuss asbestos or any other exposure.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Letter to the editor commenting on an earlier article, briefly reporting the authors' own earlier comparative study of tumour tissue stains
• Who was studied: Tumour tissue from 26 pleural mesotheliomas and 39 lung carcinomas; where and when the samples were collected is not stated in the letter
• Exposure: Not addressed; the letter concerns laboratory stains for diagnosis and does not discuss asbestos or any other exposure
• Main results:
  • CEA was absent in the 26 pleural mesotheliomas, but 10 of 39 lung (pulmonary) carcinomas were also CEA-negative
  • The authors felt the other markers studied (EMA and cytokeratin) added little to morphological assessment
  • In some mesotheliomas the CAM 5.2 cytokeratin stain showed a 'falling-apart' pattern the authors had not seen in adenocarcinomas of the lung or elsewhere
  • Absence of the 'falling-apart' pattern was inconclusive, as with CEA positivity
• The authors' conclusion: The authors concluded that immunostains may be of value in distinguishing mesothelioma from metastatic adenocarcinoma, but that great care must be taken in the choice of antibodies
• Limitations the authors state:
  • The authors noted that their earlier interpretation of cytokeratin in spindle cells as a marker of mesothelial origin is undermined because cytokeratin has since been found in mesenchymal tissues and tumours

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Malignant Mesothelioma.

Related studies

• Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study — A. Marabelle, M. Fakih, et al. (2020)
• Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases — P. Chu, E. Wu, et al. (2000)
• Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics — L.A. Doyle, M. Vivero, et al. (2014)
• GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors — M. Miettinen, P.A. McCue, et al. (2014)
• Integrative Molecular Characterization of Malignant Pleural Mesothelioma — J. Hmeljak, F. Sanchez-Vega, et al. (2018)
• Mesothelin-family proteins and diagnosis of mesothelioma — B.W. Robinson, J. Creaney, et al. (2003)

Browse more research in Journal of the Royal Society of Medicine, or return to medical research.